Lincoln Pharmaceuticals Ltd continues to invest in upgrading manufacturing capacity, new product development and expand global footprints.

For the next phase of growth, company is building a strong portfolio in lifestyle and chronic segment especially women healthcare and dermatology to complement its strong presence in acute segment.

The company is maintaining healthy growth in revenue and profitability and expects to continue the growth momentum. The company is able to grow the revenue at double digit over the last 4 years with an impressive 30% compound annual growth rate (CAGR) growth in net profit.

The company is also confident of achieving improved performance and maximize shareholders’ wealth in the near to medium term with best in class R&D capabilities supported by strong industry experience and improving market dynamics.

Mahendra Patel, MD, Lincoln Pharmaceuticals said, "For the third quarter, the company's growth was attributed to a strong performance in the domestic and international markets, new product approvals, better margin products, healthy customer and product base coupled with cost-effective strategies to improve operational efficiency. Export is the focus area for the company as margins are better and also the fact that off-late a lot of issues like price control, ban on fixed dosage combination (FDC) drugs, sale of generic drugs etc have cropped up in the domestic market.”

“The company has a presence in more than 60 countries encompassing Africa, Central America and Southeast Asia and expanding its presence gradually in more countries. We have received many product registrations in countries like East and West Africa, South East Asia and Latin America,” added Patel.

Established in the year 1979, Lincoln Pharmaceuticals has developed over 300 plus formulations in 15 therapeutic areas and has a strong product/brand portfolio in anti-infective, respiratory system, gynecology, cardio & CNS, anti-bacterial, anti-diabetic and anti-malaria among others. Company has the vision to enter the league of 'Top 50 pharmacos' of India in the near future.